GRFS

Grifois, S.A.

7.89

USD

GRFS Earnings Reports

Positive Surprise Ratio

GRFS beat 2 of 5 last estimates.

40%

Next Report

Date of Next Report

May 11, 2026

Estimate for Q1 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

Implied change from Q1 25 (Revenue/ EPS)

Grifois, S.A. earnings per share and revenue

On Feb 27, 2026, GRFS reported earnings of 0.22 USD per share (EPS) for Q4 25, beating the estimate of 0.20 USD, resulting in a 10.40% surprise. Revenue reached 3.85 billion, compared to an expected 3.68 billion, with a 4.54% difference. The market reacted with a +1.56% price change (close before vs. close after earnings).

Looking ahead to Q1 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Oruka Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.64

Actual

-$0.45

Surprise

+29.69%

Nektar Therapeutics

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.52

Actual

-$1.78

Surprise

+29.47%

Savara Inc.

Report Date

Mar 13, 2026 For Q4 25

Estimate

-$0.12

Actual

-$0.13

Surprise

-8.15%

Lyell Immunopharma, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.27

Actual

-$7.50

Surprise

-229.53%

Minerva Neurosciences, Inc

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.30

Actual

-$0.64

Surprise

-109.15%

Century Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.28

Actual

-$0.22

Surprise

+23.88%

Tonix Pharmaceuticals Holding Corp.

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$3.25

Actual

-$3.98

Surprise

-22.32%

Korro Bio, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.10

Actual

-$1.65

Surprise

+21.74%

Verrica Pharmaceuticals Inc. Common Stock

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.81

Actual

-$0.46

Surprise

+43.22%

Champions Oncology, Inc.

Report Date

Mar 12, 2026 For Q3 26

Estimate

$0.09

Actual

-$0.02

Surprise

-121.79%

FAQ

What were Grifois, S.A.'s earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Grifois, S.A. reported EPS of $0.22, beating estimates by 10.4%, and revenue of $3.85B, 4.54% above expectations.

How did the market react to Grifois, S.A.'s Q4 2025 earnings?

The stock price moved up 1.56%, changed from $8.96 before the earnings release to $9.10 the day after.

When is Grifois, S.A. expected to report next?

The next earning report is scheduled for May 11, 2026.

What are the forecasts for Grifois, S.A.'s next earnings report?

Based on -- analysts, Grifois, S.A. is expected to report EPS of -- and revenue of -- for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.